Clinical Trial

Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine)

Name: Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine) — clinical trial record (NCT07691190)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1

View on ClinicalTrials.gov →

Summary

Single dose oral bioequivalence study of Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine hydrochloride) and Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine) in healthy adult human participants under fasting conditions.

Trial Details

NCT Number	NCT07691190
Lead Sponsor	Humanis Saglık Anonim Sirketi
Conditions	SCHIZOPHRENIA 1 (Disorder)
Enrollment	32 participants
Start Date	2026-03-05
Primary Completion	2026-06-02 (estimated)
Study Completion	2026-06-26 (estimated)
Updated on ClinicalTrials.gov	2026-07-08